“去化疗”热度不减，ADC如何在其中发挥作用？

参考文献：

1. St Laurent J, Liu JF. Treatment Approaches for Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2024;42(2):127-133. .

2. Patel A, Kalachand R, Busschots S, et al. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2022;7(7):CD008766. Published 2022 Jul 12.

3. 陈昌贤, 李力. 关于卵巢上皮性癌复发患者去化疗处理的若干思考 [J] . 中华妇产科杂志, 2021, 56(9) : 593-597.

4. El Bairi K, Al Jarroudi O, Afqir S. Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. Semin Cancer Biol. 2021;77:42-55.

5. Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023;389(23):2162-2174.

6. McNamara B, Greenman M, Pebley N, Mutlu L, Santin AD. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules. 2023;28(21):7389.

7. Luke JJ, Barlesi F, Chung K, et al. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021;9(2):e002015.

8. Stewart D, Cristea M. Antibody-drug conjugates for ovarian cancer: current clinical development. Curr Opin Obstet Gynecol. 2019;31(1):18-23.

9. Cheng X, Li P, Jiang R, Meng E, Wu H. ADC: a deadly killer of platinum resistant ovarian cancer. J Ovarian Res. 2024;17(1):196.